José C. Armario-Hita

Professor of Dermatology

Universidad de Cádiz

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

José C. Armario-Hita is a Professor of Dermatology at the University of Cádiz, Spain. His research focuses on the mechanisms, diagnostics, and therapeutic advancements in dermatology, particularly in conditions such as atopic dermatitis, prurigo nodularis, and psoriasis. He has contributed to the field through various recent articles that examine treatment effectiveness, safety, and the use of decision analysis methodologies in clinical practice.

Articles (15)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (4)

Ricardo Ruiz-Villaverde

SPAIN

View details

José Manuel Dodero Anillo

Sanitary Vinculated Proffesor

Universidad de Cádiz

SPAIN

View details

Jose-Juan Pereyra-Rodriguez

SPAIN

View details

jose-manuel carrascosa

head of department, associated professor

Hospital Universitari Germans Trias i Pujol

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

José C. Armario-Hita

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi‐Criteria Decision Analysis

Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”

Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Mechanism, Diagnostic and Therapeutic Novelties in Dermatology: Where Are We Going?

Assessing the value of moderate‐to‐severe atopic dermatitis treatment using multi‐criteria decision analysis (MCDA)

Upadacitinib for moderate to severe atopic dermatitis

Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives

Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)

Unveiling the true costs and societal impacts of moderate‐to‐severe atopic dermatitis in Europe

104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain

Drug survival of systemic and biological treatments for moderate‐to‐severe atopic dermatitis in adults: a multicentre retrospective observational study

Efficiency in patch testing: the number needed to test to get one relevant result as a new approach in the evaluation of baseline series

Collaborators (4)

Ricardo Ruiz-Villaverde

José Manuel Dodero Anillo

Jose-Juan Pereyra-Rodriguez

jose-manuel carrascosa

Make your next move.